|
ADDITIVE IMMUNOSUPRESSION
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
VACCINATION WITH LIVE VIRUS / BACTERIA MAY CAUSE LIFE THREATENING COMPLICATIONS DUE TO POOR BODY IMMUNITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
DISULFIRAM LIKE REACTION WITH ALCOHOL
|
CONCURRENT AND/OR SEQUENTIAL USE WITH A WEAK MAO INHIBITORS LIKE PROCARBAZINE IS RARELY ASSOCIATED WITH SEVERE & SOMETIMES FATAL REACTIONS BUT CARE SHOULD ALWAYS BE TAKEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
ANTINEOPLASTICS MAY DECREASE GASTRIC ABSORPTION OF THE DRUGS DUE TO DAMAGE TO THE GASTROINTESTINAL MUCOSA
|
MAOIS INHIBIT THE DRUG METABOLIZING ENZYMES, WHICH MAY ENHANCE THE EFFECTS OF BARBITURATE, HYPNOTICS, HYPOGLYCAENICS & ANTIMUSCARINICS
|
MAOIS MAY CAUSE ELEVATED BLOOD PRESSURE IF USED CONCURRENTLY
|
MAOIS CAN CAUSE SEVERE HYPOTENSION WHEN GIVEN CONCURRENTLY
|
MAOIS CONCURRENT USE WITH THE DRUG IS ASSOCIATED WITH SEVERE AND SOMETIMES FATAL REACTIONS
|
TETRABENAZINE IF GIVEN FOLLOWING A COURSE OF MAO INHIBITORS, LEADS TO CONFUSION, RESTLESSNESS & DISORIENTATION
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
MAY POTENTIATE HYPOTENSIVE EFFECTS
|
MAY POTENTIATE HYPOTENSIVE EFFECTS
|
MAY POTENTIATE HYPOTENSIVE EFFECTS
|
MAY POTENTIATE HYPOTENSIVE EFFECTS
|
MAY POTENTIATE HYPOTENSIVE EFFECTS
|